Related references
Note: Only part of the references are listed.Discovery of JNJ-63576253: A Clinical Stage Androgen Receptor Antagonist for F877L Mutant and Wild-Type Castration-Resistant Prostate Cancer (mCRPC)
Zhuming Zhang et al.
JOURNAL OF MEDICINAL CHEMISTRY (2021)
Structure-Activity Relationships for the Marine Natural Product Sintokamides: Androgen Receptor N-Terminus Antagonists of Interest for Treatment of Metastatic Castration-Resistant Prostate Cancer
Luping Yan et al.
JOURNAL OF NATURAL PRODUCTS (2021)
Cancer statistics, 2020
Rebecca L. Siegel et al.
CA-A CANCER JOURNAL FOR CLINICIANS (2020)
New steroidal oxazolines, benzoxazoles and benzimidazoles related to abiraterone and galeterone
Alexandra S. Latysheva et al.
STEROIDS (2020)
The splicing modulator sulfonamide indisulam reduces AR-V7 in prostate cancer cells
James E. Melnyk et al.
BIOORGANIC & MEDICINAL CHEMISTRY (2020)
Combination therapy with androgen receptor N-terminal domain antagonist EPI-7170 and enzalutamide yields synergistic activity in AR-V7-positive prostate cancer
Yukiyoshi Hirayama et al.
MOLECULAR ONCOLOGY (2020)
Systematic Investigation of the Permeability of Androgen Receptor PROTACs
Duncan E. Scott et al.
ACS MEDICINAL CHEMISTRY LETTERS (2020)
Pyrazol-1-yl-propanamides as SARD and Pan-Antagonists for the Treatment of Enzalutamide-Resistant Prostate Cancer
Yali He et al.
JOURNAL OF MEDICINAL CHEMISTRY (2020)
A highly potent PROTAC androgen receptor (AR) degrader ARD-61 effectively inhibits AR-positive breast cancer cell growth in vitro tumor growth in vivo
Lijie Zhao et al.
NEOPLASIA (2020)
The Androgen Receptor in Prostate Cancer: Effect of Structure, Ligands and Spliced Variants on Therapy
Elisabeth A. Messner et al.
BIOMEDICINES (2020)
Prospective Multicenter Study of Circulating Tumor Cell AR-V7 and Taxane Versus Hormonal Treatment Outcomes in Metastatic Castration-Resistant Prostate Cancer
Andrew J. Armstrong et al.
JCO PRECISION ONCOLOGY (2020)
Androgen receptor modulators: a review of recent patents and reports (2012-2018)
Shinya Fujii et al.
EXPERT OPINION ON THERAPEUTIC PATENTS (2019)
Targeting Nuclear Receptors with PROTAC degraders
John J. Flanagan et al.
MOLECULAR AND CELLULAR ENDOCRINOLOGY (2019)
Androgen Receptor-Directed Molecular Conjugates for Targeting Prostate Cancer
Giovanni L. Beretta et al.
FRONTIERS IN CHEMISTRY (2019)
Orally Bioavailable Androgen Receptor Degrader, Potential Next-Generation Therapeutic for Enzalutamide-Resistant Prostate Cancer
Suriyan Ponnusamy et al.
CLINICAL CANCER RESEARCH (2019)
Galeterone and The Next Generation Galeterone Analogs, VNPP414 and VNPP433-3β Exert Potent Therapeutic Effects in Castration-/Drug-Resistant Prostate Cancer Preclinical Models In Vitro and In Vivo
Andrew K. Kwegyir-Afful et al.
CANCERS (2019)
New Generation of Selective Androgen Receptor Degraders: Our Initial Design, Synthesis, and Biological Evaluation of New Compounds with Enzalutamide-Resistant Prostate Cancer Activity
Dong-Jin Hwang et al.
JOURNAL OF MEDICINAL CHEMISTRY (2019)
Discovery of ARD-69 as a Highly Potent Proteolysis Targeting Chimera (PROTAC) Degrader of Androgen Receptor (AR) for the Treatment of Prostate Cancer
Xin Han et al.
JOURNAL OF MEDICINAL CHEMISTRY (2019)
Selective Androgen Receptor Modulators: Current Knowledge and Clinical Applications
Zachary J. Solomon et al.
SEXUAL MEDICINE REVIEWS (2019)
Development of Protein Degradation Inducers of Androgen Receptor by Conjugation of Androgen Receptor Ligands and Inhibitor of Apoptosis Protein Ligands
Norihito Shibata et al.
JOURNAL OF MEDICINAL CHEMISTRY (2018)
Selective modulation of the androgen receptor AF2 domain rescues degeneration in spinal bulbar muscular atrophy
Nisha M. Badders et al.
NATURE MEDICINE (2018)
Selectively targeting the dimerization interface of human androgen receptor with small-molecules to treat castration-resistant prostate cancer
Kush Dalal et al.
CANCER LETTERS (2018)
Degradation of Androgen Receptor through Small Molecules for Prostate Cancer
Raoling Ge et al.
CURRENT CANCER DRUG TARGETS (2018)
Structural Based Screening of Antiandrogen Targeting Activation Function-2 Binding Site
Yangguang Liu et al.
FRONTIERS IN PHARMACOLOGY (2018)
Bypassing Drug Resistance Mechanisms of Prostate Cancer with Small Molecules that Target Androgen Receptor-Chromatin Interactions
Kush Dalal et al.
MOLECULAR CANCER THERAPEUTICS (2017)
Structure of the homodimeric androgen receptor ligand-binding domain
Marta Nadal et al.
NATURE COMMUNICATIONS (2017)
Androgen receptor splice variants and prostate cancer: From bench to bedside
Kristine M. Wadosky et al.
Oncotarget (2017)
Novel Selective Agents for the Degradation of Androgen Receptor Variants to Treat Castration-Resistant Prostate Cancer
Suriyan Ponnusamy et al.
CANCER RESEARCH (2017)
Androgen Receptor Pathway-Independent Prostate Cancer Is Sustained through FGF Signaling
Eric G. Bluemn et al.
CANCER CELL (2017)
Steroidogenic Metabolism of Galeterone Reveals a Diversity of Biochemical Activities
Mohammad Alyamani et al.
CELL CHEMICAL BIOLOGY (2017)
Synthesis and biological evaluation of novel selective androgen receptor modulators (SARM-s) Part Ill: Discovery of 4-(5-oxopyrrolidine-1-yl) benzonitrile derivative 2f as a clinical candidate
Katsuji Aikawa et al.
BIOORGANIC & MEDICINAL CHEMISTRY (2017)
EPI-001, A Compound Active against Castration-Resistant Prostate Cancer, Targets Transactivation Unit 5 of the Androgen Receptor
Eva De Mol et al.
ACS CHEMICAL BIOLOGY (2016)
Practical synthesis of a phthalimide-based Cereblon ligand to enable PROTAC development
Jasmin Lohbeck et al.
BIOORGANIC & MEDICINAL CHEMISTRY LETTERS (2016)
ASC-J9® suppresses castration resistant prostate cancer progression via degrading the enzalutamide-induced androgen receptor mutant AR-F876L
Ronghao Wang et al.
CANCER LETTERS (2016)
Sintokamide A Is a Novel Antagonist of Androgen Receptor That Uniquely Binds Activation Function-1 in Its Amino-terminal Domain
Carmen A. Banuelos et al.
JOURNAL OF BIOLOGICAL CHEMISTRY (2016)
2-Chloro-4-[[(1R,2R)-2-hydroxy-2-methyl-cyclopentyl]amino]-3-methyl-benzonitrile: A Transdermal Selective Androgen Receptor Modulator (SARM) for Muscle Atrophy
Ashraf Saeed et al.
JOURNAL OF MEDICINAL CHEMISTRY (2016)
Niclosamide enhances abiraterone treatment via inhibition of androgen receptor variants in castration resistant prostate cancer
Chengfei Liu et al.
ONCOTARGET (2016)
Role of androgen receptor splice variants in prostate cancer metastasis
Jin Xu et al.
ASIAN JOURNAL OF UROLOGY (2016)
AZD3514, an oral selective androgen receptor down-regulator in patients with castration-resistant prostate cancer - results of two parallel first-in-human phase I studies
A. Omlin et al.
INVESTIGATIONAL NEW DRUGS (2015)
Discovery and Development of Galeterone (TOK-001 or VN/124-1) for the Treatment of All Stages of Prostate Cancer
Vincent C. O. Njar et al.
JOURNAL OF MEDICINAL CHEMISTRY (2015)
Interaction mechanism exploration of R-bicalutamide/S-1 with WT/W741L AR using molecular dynamics simulations
Hongli Liu et al.
MOLECULAR BIOSYSTEMS (2015)
Galeterone and VNPT55 induce proteasomal degradation of AR/AR-V7, induce significant apoptosis via cytochrome c release and suppress growth of castration resistant prostate cancer xenografts in vivo
Andrew K. Kwegyir-Afful et al.
ONCOTARGET (2015)
Proposed Morphologic Classification of Prostate Cancer With Neuroendocrine Differentiation
Jonathan I. Epstein et al.
AMERICAN JOURNAL OF SURGICAL PATHOLOGY (2014)
Galeterone Prevents Androgen Receptor Binding to Chromatin and Enhances Degradation of Mutant Androgen Receptor
Ziyang Yu et al.
CLINICAL CANCER RESEARCH (2014)
Niclosamide Inhibits Androgen Receptor Variants Expression and Overcomes Enzalutamide Resistance in Castration-Resistant Prostate Cancer
Chengfei Liu et al.
CLINICAL CANCER RESEARCH (2014)
Selectively Targeting the DNA-binding Domain of the Androgen Receptor as a Prospective Therapy for Prostate Cancer
Kush Dalal et al.
JOURNAL OF BIOLOGICAL CHEMISTRY (2014)
Discovery of Small-Molecule Inhibitors Selectively Targeting the DNA-Binding Domain of the Human Androgen Receptor
Huifang Li et al.
JOURNAL OF MEDICINAL CHEMISTRY (2014)
Identification of a new androgen receptor (AR) co-regulator BUD31 and related peptides to suppress wild-type and mutated AR-mediated prostate cancer growth via peptide screening and X-ray structure analysis
Cheng-Lung Hsu et al.
MOLECULAR ONCOLOGY (2014)
Characterization of Niphatenones that Inhibit Androgen Receptor N-Terminal Domain
Carmen A. Banuelos et al.
PLOS ONE (2014)
Androgen Receptor Gene Rearrangements: New Perspectives on Prostate Cancer Progression
Lucas J. Brand et al.
CURRENT DRUG TARGETS (2013)
An androgen receptor N-terminal domain antagonist for treating prostate cancer
Jae-Kyung Myung et al.
JOURNAL OF CLINICAL INVESTIGATION (2013)
Targeting the Binding Function 3 (BF3) Site of the Androgen Receptor Through Virtual Screening. 2. Development of 2-((2-phenoxyethyl) thio)-1H-benzimidazole Derivatives
Ravi Shashi Nayana Munuganti et al.
JOURNAL OF MEDICINAL CHEMISTRY (2013)
An F876L Mutation in Androgen Receptor Confers Genetic and Phenotypic Resistance to MDV3100 (Enzalutamide)
Manav Korpal et al.
CANCER DISCOVERY (2013)
Overcoming mutation-based resistance to antiandrogens with rational drug design
Minna D. Balbas et al.
ELIFE (2013)
Distinct Transcriptional Programs Mediated by the Ligand-Dependent Full-Length Androgen Receptor and Its Splice Variants in Castration-Resistant Prostate Cancer
Rong Hu et al.
CANCER RESEARCH (2012)
Recent developments in antiandrogens and selective androgen receptor modulators
Bernard Haendler et al.
MOLECULAR AND CELLULAR ENDOCRINOLOGY (2012)
Intrinsic disorder in the androgen receptor: identification, characterisation and drugability
Iain J. McEwan
MOLECULAR BIOSYSTEMS (2012)
Discovery of Aryloxy Tetramethylcyclobutanes as Novel Androgen Receptor Antagonists
Chuangxing Guo et al.
JOURNAL OF MEDICINAL CHEMISTRY (2011)
Targeting the Binding Function 3 (BF3) Site of the Human Androgen Receptor through Virtual Screening
Nathan A. Lack et al.
JOURNAL OF MEDICINAL CHEMISTRY (2011)
Regression of Castrate-Recurrent Prostate Cancer by a Small-Molecule Inhibitor of the Amino-Terminus Domain of the Androgen Receptor
Raymond J. Andersen et al.
CANCER CELL (2010)
Integrative Genomic Profiling of Human Prostate Cancer
Barry S. Taylor et al.
CANCER CELL (2010)
Targeted intracellular protein degradation induced by a small molecule: En route to chemical proteomics
Ashley R. Schneekloth et al.
BIOORGANIC & MEDICINAL CHEMISTRY LETTERS (2008)
Structural basis for accommodation of nonsteroidal ligands in the androgen receptor
CE Bohl et al.
JOURNAL OF BIOLOGICAL CHEMISTRY (2005)
Design, synthesis, and biological characterization of metabolically stable selective androgen receptor modulators
CA Marhefka et al.
JOURNAL OF MEDICINAL CHEMISTRY (2004)
Androgen-independent prostate cancer is a heterogeneous group of diseases: Lessons from a rapid autopsy program
RB Shah et al.
CANCER RESEARCH (2004)
Pharmacodynamics of selective androgen receptor modulators
DH Yin et al.
JOURNAL OF PHARMACOLOGY AND EXPERIMENTAL THERAPEUTICS (2003)
Protacs: Chimeric molecules that target proteins to the Skp1-Cullin-F box complex for ubiquitination and degradation
KM Sakamoto et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2001)
Crystallographic structures of the ligand-binding domains of the androgen receptor and its T877A mutant complexed with the natural agonist dihydrotestosterone
JS Sack et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2001)
Glucocorticoids can promote androgen-independent growth of prostate cancer cells through a mutated androgen receptor
XY Zhao et al.
NATURE MEDICINE (2000)
Share Paper
